Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

AstraZeneca gets rights to AtheroGenics's AGI1067; terminated

Executive Summary

AstraZeneca has licensed exclusive worldwide development and commercialization rights to AtheroGenics' (inflammatory disease therapeutics) AGI1067 for atherosclerosis. The oral compound blocks signaling pathways in endothelial cells that are involved in chronic cardiovascular inflammation and atherosclerosis.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing
    • Includes Contract
    • Co-Promotion

Related Companies

UsernamePublicRestriction

Register